Literature DB >> 26115110

Can didactic continuing education improve clinical decision making and reduce cost of quality? Evidence from a case study.

Mira Vuković, Branislav S Gvozdenović, Milena Ranković, Bryan P McCormick, Danica D Vuković, Biljana D Gvozdenović, Dragana A Kastratović, Srdjan Z Marković, Miodrag Ilić, Mihajlo B Jakovljević.   

Abstract

INTRODUCTION: Administration of human serum albumin (HSA) solutions for the resuscitation of critically ill patients remains controversial. The objective of this study was to assess the effect of continuing medical education (CME) on health care professionals' clinical decision making with regard to HSA administration and the costs of quality (COQ). A quasi-experimental study of time series association of CME intervention with COQ and use of HSA solution was conducted at the Surgery Department of the Hospital Valjevo, Serbia. The CME contained evidence-based criteria for HSA solution administration in surgical patients. The preintervention period was defined as January 2009 to May 2011. CME was provided in June 2011, with the postintervention period June 2011 to May 2012.
METHODS: Total mortality rate, the rate of nonsurgical mortality, the rate of surgical mortality, the rate of sepsis patient mortality, index of irrational use of HSA solutions, and number of hospital days per hospitalized patient were collected for each month as quality indicators. Statistical analysis was performed by multivariate autoregressive integrated moving average (MARIMA) modeling. The specification of the COQ was performed according to a traditional COQ model.
RESULTS: The CME intervention resulted in an average monthly reduction of the hospital days per hospitalized patient, the rate of sepsis patient mortality, index of irrational use of HSA solutions, and COQ for $593,890.77 per year. DISCUSSION: Didactic CME presenting evidence-based criteria for HSA administration was associated with improvements in clinical decisions and COQ. In addition, this study demonstrates that models combining MARIMA and traditional COQ models can be useful in the evaluation of CME interventions aimed at reducing COQ.
© 2015 The Alliance for Continuing Education in the Health Professions, the Society for Academic Continuing Medical Education, and the Council on Continuing Medical Education, Association for Hospital Medical Education.

Entities:  

Keywords:  cost of quality; cost/benefit-cost/effectiveness analysis; human serum albumin; innovative educational interventions; mortality; quality improvement/Six Sigma/TQM; quality indicators; surgery department

Mesh:

Substances:

Year:  2015        PMID: 26115110     DOI: 10.1002/chp.21272

Source DB:  PubMed          Journal:  J Contin Educ Health Prof        ISSN: 0894-1912            Impact factor:   1.355


  5 in total

1.  Global pharmaceutical regulation: the challenge of integration for developing states.

Authors:  Anthony Pezzola; Cassandra M Sweet
Journal:  Global Health       Date:  2016-12-20       Impact factor: 4.185

2.  Improvements in Neonatal and Childhood Medical Care - Perspective from the Balkans.

Authors:  Vesna Velickovic; Aleksandra Simovic; Gordana Lazarevic; Marija Lazarevic; Mihajlo Jakovljevic
Journal:  Front Public Health       Date:  2015-08-27

3.  When cure becomes an illness-abuse of addictive prescription medicines.

Authors:  Mihajlo Michael Jakovljevic; Marija Lazarevic; Milena Jurisevic; Mirjana R Jovanovic
Journal:  Front Pharmacol       Date:  2015-09-15       Impact factor: 5.810

4.  How Do Primary Care Physicians Perceive the Role of Nurses in Quality Measurement and Improvement? The Israeli Story.

Authors:  Rachel Nissanholtz-Gannot; Dorit Goldman; Bruce Rosen; Calanit Kay; Rachel Wilf-Miron
Journal:  Front Public Health       Date:  2016-06-22

5.  Capitation-Based Financing Hampers the Provision of Preventive Services in Primary Health Care.

Authors:  János Sándor; Karolina Kósa; Magor Papp; Gergő Fürjes; László Kőrösi; Mihajlo Jakovljevic; Róza Ádány
Journal:  Front Public Health       Date:  2016-09-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.